Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795252

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1795252

Janus Kinase (JAK) Inhibitors

PUBLISHED:
PAGES: 179 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Janus Kinase (JAK) Inhibitors Market to Reach US$32.7 Billion by 2030

The global market for Janus Kinase (JAK) Inhibitors estimated at US$11.7 Billion in the year 2024, is expected to reach US$32.7 Billion by 2030, growing at a CAGR of 18.6% over the analysis period 2024-2030. Autoimmune Disorders Application, one of the segments analyzed in the report, is expected to record a 20.7% CAGR and reach US$22.9 Billion by the end of the analysis period. Growth in the Oncology Application segment is estimated at 14.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 25.6% CAGR

The Janus Kinase (JAK) Inhibitors market in the U.S. is estimated at US$3.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 25.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.6% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.6% CAGR.

Global Janus Kinase (JAK) Inhibitors Market - Key Trends & Drivers Summarized

Why Are Janus Kinase Inhibitors Revolutionizing the Management of Inflammatory and Autoimmune Diseases?

Janus kinase (JAK) inhibitors have rapidly emerged as a transformative therapeutic option in the management of a broad range of chronic inflammatory and autoimmune conditions due to their targeted mechanism of action, rapid symptom control, and oral availability. These small-molecule drugs interrupt intracellular signaling pathways mediated by cytokines, which are central to the pathogenesis of disorders like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and ankylosing spondylitis. By modulating the JAK-STAT signaling cascade, JAK inhibitors can downregulate immune overactivity without the broad immunosuppressive effects associated with corticosteroids or traditional disease-modifying antirheumatic drugs (DMARDs). Their oral administration also offers an appealing alternative to injectable biologics, improving adherence and convenience for patients. Clinicians increasingly view JAK inhibitors as a valuable option for patients with refractory disease or those who fail to respond adequately to existing biologics. Additionally, many of these therapies demonstrate rapid onset of action, providing symptom relief within days or weeks, which is crucial for improving quality of life and reducing disability. Regulatory approvals for newer indications such as alopecia areata and vitiligo further underscore the expanding clinical footprint of this drug class. With chronic autoimmune conditions rising globally due to lifestyle changes, environmental factors, and improved diagnosis rates, the role of JAK inhibitors is becoming increasingly central in both frontline and second-line treatment strategies.

How Is Innovation in Molecular Targeting and Formulation Driving the Evolution of JAK Inhibitor Therapies?

The scientific landscape surrounding JAK inhibitors is evolving rapidly as researchers refine selectivity, enhance safety profiles, and expand the scope of therapeutic indications. Initial generations of JAK inhibitors were pan-inhibitors, targeting multiple JAK isoforms simultaneously, which raised concerns about off-target effects and infections. However, the latest wave of development focuses on isoform-specific inhibitors that preferentially target JAK1, JAK2, or TYK2, aiming to reduce adverse events such as thromboembolic complications and lipid abnormalities. Pharmaceutical companies are employing advanced molecular modeling and structure-based drug design to create compounds with greater binding precision and metabolic stability. Extended-release formulations and dual-action molecules are being explored to improve pharmacokinetics and allow once-daily or even weekly dosing regimens. Combination therapies that pair JAK inhibitors with biologics or conventional DMARDs are under clinical evaluation to improve efficacy in complex cases. Additionally, topical formulations are being developed for dermatological conditions, allowing localized treatment with reduced systemic exposure. Companion diagnostics and pharmacogenomic tools are also being integrated into clinical workflows to better match patients with the most appropriate JAK inhibitor based on genetic profiles and disease biomarkers. The robust clinical pipeline includes candidates for hard-to-treat conditions such as lupus, multiple sclerosis, graft-versus-host disease, and type 1 diabetes. These innovations are not only improving therapeutic outcomes but also expanding the potential patient base, reinforcing JAK inhibitors’ position as a cornerstone of precision immunotherapy.

How Do Regulatory Trends and Safety Concerns Influence the Commercial Outlook for JAK Inhibitors?

Regulatory agencies play a critical role in shaping the commercial and clinical trajectory of JAK inhibitors, particularly as safety concerns emerge in long-term post-marketing surveillance. The US FDA, EMA, and other health authorities have implemented heightened scrutiny following signals of increased cardiovascular events, malignancies, and serious infections in patients treated with certain JAK inhibitors. As a result, boxed warnings and restricted indications have been added to drug labels, and risk evaluation and mitigation strategies (REMS) have been introduced to guide prescribing practices. These regulatory responses have prompted pharmaceutical companies to invest heavily in real-world evidence studies and post-approval registries to monitor patient safety across broader populations. In parallel, payers are becoming more selective in their reimbursement criteria, requiring evidence of superior benefit-risk profiles before approving coverage, especially when lower-cost biologics or biosimilars are available. Despite these hurdles, demand remains strong due to the therapeutic value of JAK inhibitors in patient populations that are non-responsive or intolerant to other therapies. Market access strategies now often include education programs for healthcare professionals, digital adherence tools, and partnerships with advocacy groups to support informed decision-making. Additionally, regional regulatory divergence is influencing global commercialization efforts, with faster approvals and broader indications granted in some emerging markets where access to biologics is limited. While the safety narrative presents a challenge, it is also catalyzing industry innovation to produce safer, more selective compounds and to differentiate JAK inhibitors from both traditional immunosuppressants and newer biologics.

What Factors Are Driving the Continued Growth of the Global JAK Inhibitors Market?

The growth in the Janus kinase (JAK) inhibitors market is driven by several interrelated factors spanning clinical, technological, economic, and demographic dimensions. Rising prevalence of autoimmune and chronic inflammatory conditions, particularly in aging populations and industrialized nations, is expanding the eligible patient pool for JAK-targeted therapies. Patient preference for oral medications over injectables is pushing physicians to prescribe JAK inhibitors more frequently, especially for individuals requiring long-term treatment. Pharmaceutical innovation is continuously enhancing drug safety, efficacy, and tolerability, resulting in a steady pipeline of next-generation JAK inhibitors with differentiated profiles. Expanding label approvals into dermatology, gastroenterology, and rare autoimmune diseases are increasing product utility across multiple specialties. Competitive dynamics are also contributing to market expansion, as biosimilars and generic alternatives place downward pressure on pricing, making therapies more accessible in middle-income regions. Increased physician awareness, better diagnostic tools, and improved disease classification are enabling earlier intervention with targeted treatments like JAK inhibitors. Health systems under pressure to deliver outcomes at lower costs are recognizing the value of these drugs in reducing hospitalization, surgeries, and long-term complications. Payer models are evolving to reward real-world effectiveness, which favors fast-acting therapies with proven patient-reported outcomes. Global investment in immunology research, combined with the decentralization of clinical trials to reach more diverse populations, is accelerating innovation and market reach. These combined forces are ensuring that JAK inhibitors will remain a high-growth segment of the pharmaceutical industry, meeting the urgent needs of patients while driving revenue opportunities for drug developers worldwide.

SCOPE OF STUDY:

The report analyzes the Janus Kinase (JAK) Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Autoimmune Disorders Application, Oncology Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celon Pharma S.A.
  • Confluence Life Sciences, Inc.
  • CTI BioPharma Corp.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Jiangsu Hengrui Pharmaceuticals Co.
  • Pfizer Inc.
  • Prometheus Biosciences, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Sierra Oncology, Inc.
  • Sino Biopharmaceutical Limited
  • SOTIO Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Tiziana Life Sciences Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37225

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Janus Kinase (JAK) Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Expanding Autoimmune Disease Prevalence Propels Growth of JAK Inhibitor Therapeutics
    • Shift Toward Targeted Small Molecule Therapies Strengthens Business Case for JAK Inhibition
    • Advancements in Immunology Research Throw the Spotlight on JAK Pathway as a Drug Target
    • Increasing Adoption in Dermatological Indications Accelerates Demand for Topical and Oral JAK Inhibitors
    • Pipeline Diversification in Oncology Expands Addressable Market for Next-Generation JAK Inhibitors
    • Favorable Clinical Outcomes in Rheumatoid Arthritis Drive Adoption Across Autoimmune Segments
    • Payer Pressure and Cost Sensitivities Spur Interest in Oral JAK Inhibitors Over Biologics
    • Patient Preference for Oral Administration Sustains Growth in Chronic Disease Management
    • Biomarker-Guided Therapy Development Throws the Spotlight on Personalized JAK Inhibitor Strategies
    • Expanding Geriatric Population Drives Demand for Convenient, Long-Term Immunomodulation Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Janus Kinase (JAK) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Autoimmune Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Autoimmune Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • CHINA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • INDIA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Janus Kinase (JAK) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Janus Kinase (JAK) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Janus Kinase (JAK) Inhibitors by Application - Autoimmune Disorders Application and Oncology Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Janus Kinase (JAK) Inhibitors by Application - Percentage Breakdown of Value Sales for Autoimmune Disorders Application and Oncology Application for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!